Renal Physiology

Answer Card

What are the fundamental components of renal physiology critical to intensive care?

Renal physiology encompasses nephron anatomy and function, glomerular filtration, renal blood flow autoregulation, tubular transport processes (Na+/K+ handling, urine concentration), the renin-angiotensin-aldosterone system (RAAS), antidiuretic hormone (ADH) action, renal oxygenation, acid-base homeostasis, and glomerular filtration rate (GFR) measurement. These systems maintain fluid and electrolyte balance, blood pressure, acid-base status, and waste excretion—processes frequently disrupted in critically ill patients requiring precise monitoring and intervention. [1-5]

---

Summary

Renal physiology represents the integrated function of approximately 1 million nephrons per kidney, each performing ultrafiltration, reabsorption, and secretion to maintain homeostasis. The glomerulus filters 180 L/day of plasma, with 99% reabsorbed through highly segment-specific tubular transport mechanisms. Renal blood flow (RBF) of 1.2 L/min receives 20-25% of cardiac output yet accounts for only 7% of body weight, reflecting its high oxygen consumption of 6-8 mL O2/100g/min. Autoregulation maintains stable RBF and GFR across mean arterial pressures of 80-170 mmHg via myogenic and tubuloglomerular feedback mechanisms. The RAAS system and ADH regulate blood pressure and osmolality, while the countercurrent multiplier system in the loop of Henle enables concentration of urine to 1200 mOsm/kg. Acid-base balance involves bicarbonate reabsorption (4500 mmol/day), ammoniagenesis (adaptively increasing 5-10 fold in acidosis), and titratable acid excretion. GFR estimation uses creatinine (muscle-dependent, affected by age, sex, race) and cystatin C (muscle-independent, less variable), with combined equations improving accuracy. Critical illness disrupts these mechanisms through hypoperfusion, inflammation, nephrotoxins, and altered neurohormonal signaling, precipitating acute kidney injury and electrolyte disturbances. [1-10]

---

Detailed Content

Nephron Anatomy and Functional Segments

Each human kidney contains 800,000 to 1.5 million nephrons, classified as cortical (85%) with short loops of Henle or juxtamedullary (15%) with long loops extending into the inner medulla. [11,12] The juxtamedullary nephrons are essential for urine concentration, generating the medullary osmotic gradient.

The nephron consists of:

Renal Corpuscle:

• Glomerulus: Capillary network with fenestrated endothelium (70-100 nm pores) that prevents cellular passage while allowing plasma filtration. [13]
• Bowman's capsule: Double-walled epithelial structure surrounding the glomerulus, collecting ultrafiltrate.

Glomerular Filtration Barrier (GFB): Three layers create a molecular sieve:

1. Fenestrated endothelium: Size restriction preventing blood cells (pores ~70-100 nm). [13]

2. Glomerular basement membrane (GBM): Gel-like matrix of type IV collagen, laminin, and heparan sulfate providing negative charge repelling anionic proteins like albumin. [14]

3. Podocytes: Epithelial cells with interdigitating foot processes forming slit diaphragms bridged by nephrin, podocin, and other proteins, creating the final size-selective barrier (4-11 nm). [15]

Podocyte loss is the primary driver of glomerulosclerosis and proteinuria in chronic kidney disease. Single-cell sequencing has identified transitional cell types between proximal tubule and loop of Henle involved in CKD progression. [16,17]

Tubular Segments:

Proximal Convoluted Tubule (PCT): The primary reabsorption site with high mitochondrial density reflecting active transport capacity. Reabsorbs 65% of filtered Na+ and H2O, 100% of glucose and amino acids, 85% of bicarbonate, and all phosphate at normal filtered loads. [18,19]

Loop of Henle:

• Descending limb: Highly permeable to water (aquaporin-1), impermeable to solutes.
• Thin ascending limb: Impermeable to water, passive Na+ reabsorption.
• Thick ascending limb (TAL): Impermeable to water, active Na+/K+/2Cl- transport via NKCC2, site of loop diuretic action and furosemide target. [20]

Distal Convoluted Tubule (DCT): Fine-tunes electrolyte balance. Site of thiazide-sensitive NaCl cotransporter (NCC), regulated by aldosterone and WNK kinases. [21,22]

Collecting Duct: Final site for water reabsorption via aquaporin-2 channels regulated by ADH. Contains principal cells (Na+ reabsorption via ENaC, K+ secretion) and intercalated cells (acid-base regulation). [23,24]

Juxtaglomerular Apparatus (JGA):

• Juxtaglomerular cells: Modified smooth muscle cells producing and storing renin.
• Macula densa: Specialized cells in distal TAL sensing NaCl delivery.
• Extraglomerular mesangial cells: Transmit signals between macula densa and afferent arteriole. [25]

Glomerular Filtration Physiology

Glomerular Filtration Rate (GFR): The volume of fluid filtered from glomerular capillaries into Bowman's capsule per unit time, normal 120-130 mL/min (180 L/day). [26]

Starling Forces and Ultrafiltration:

GFR = Kf × [(Pgc - Pbs) - (πgc - πbs)]

Where:

• Kf = Ultrafiltration coefficient (product of hydraulic permeability and surface area)
• Pgc = Glomerular capillary hydrostatic pressure (~55 mmHg)
• Pbs = Bowman's space hydrostatic pressure (~15 mmHg)
• πgc = Glomerular capillary oncotic pressure (~30 mmHg)
• πbs = Bowman's space oncotic pressure (~0 mmHg)

Net filtration pressure = (55 - 15) - (30 - 0) = 10 mmHg [26,27]

Filtration fraction = GFR / RPF = 125/650 = 0.19-0.20 (19-20%)

Key determinants:

• Kf depends on GFB integrity and surface area
• Pgc is influenced by afferent/efferent arteriolar resistance
• πgc increases along glomerular capillary due to water filtration [26-28]

Selective Filtration:

• Molecular size: Substances below 4 nm freely filtered; greater than 8 nm retained; albumin (3.6 nm) restricted by charge
• Charge: Negatively charged GBM and podocytes repel anionic proteins (albumin, globulins)
• Shape: Globular proteins filter more readily than elongated molecules [14,15]

Renal Blood Flow and Autoregulation

Renal Blood Flow (RBF): Approximately 1,200 mL/min (20-25% of cardiac output) for both kidneys combined, reflecting high oxygen demand. [29,30]

Renal Vascular Resistance:

• Afferent arteriole: Primary regulator of hydrostatic pressure
• Efferent arteriole: Determines filtration fraction and peritubular capillary pressure
• Glomerular capillaries: High-flow, low-resistance network [29]

Autoregulation: Maintenance of constant RBF and GFR across mean arterial pressure range of 80-170 mmHg, protecting glomeruli from hypertensive damage and ensuring stable solute delivery. [31,32]

Two primary mechanisms:

1. Myogenic Mechanism:

• Acts within 1-3 seconds
• Afferent arteriole smooth muscle responds to stretch
• Increased pressure → wall stretch → stretch-activated Ca2+ channels open → depolarization → vasoconstriction
• Decreased pressure → reduced stretch → vasodilation
• Protects against pressure-induced glomerular injury [32,33]

2. Tubuloglomerular Feedback (TGF):

• Acts within 10-20 seconds
• Macula densa senses NaCl delivery via NKCC2 transporter
• Increased NaCl delivery (indicating high GFR) → adenosine and ATP release → A1 receptor activation on afferent arteriole → vasoconstriction
• Decreased NaCl delivery → renin release → Angiotensin II → efferent arteriole constriction → GFR maintenance
• Operates as a negative feedback loop [34,35]

Integration:

• Myogenic mechanism handles high-frequency pressure fluctuations
• TGF fine-tunes GFR based on tubular flow
• Both constrict afferent arteriole to reduce GFR during increased pressure
• Synergistic interaction provides robust protection [32,35]

Clinical Relevance:

• CKD and diabetes impair autoregulation, exposing glomeruli to systemic hypertension and accelerating sclerosis
• NSAIDs inhibit prostaglandin-mediated vasodilation, reducing RBF in volume depletion
• ACE inhibitors preferentially dilate efferent arteriole, reducing intraglomerular pressure (renoprotective) but reducing GFR in renal artery stenosis
• SGLT2 inhibitors increase NaCl delivery to macula densa, activating TGF to reduce intraglomerular pressure and hyperfiltration [36,37]

Tubular Transport Mechanisms

Proximal Tubule (PT) Transport:

Sodium Reabsorption (65% of filtered load):

• NHE3 (Na+/H+ exchanger) on apical membrane: Na+ enters down electrochemical gradient, H+ secreted
• Na+-glucose cotransporters (SGLT1, SGLT2): Reabsorb all filtered glucose
• Na+-amino acid cotransporters: Reabsorb all amino acids
• Na+-phosphate cotransporter: Reabsorbs phosphate
• Na+/K+-ATPase on basolateral membrane: Pumps Na+ out, K+ in (establishes gradient) [18,19]

Water Reabsorption (65% of filtered load):

• Follows solute reabsorption iso-osmotically
• High water permeability via aquaporin-1 channels
• Creates isosmotic tubular fluid (~300 mOsm/kg) [38]

Bicarbonate Reabsorption (85% of filtered load, ~4,000 mmol/day):

• Apical: H+ secreted via NHE3 combines with filtered HCO3- → CO2 + H2O (catalyzed by carbonic anhydrase IV on brush border)
• Intracellular: CO2 + H2O → H2CO3 → H+ + HCO3- (catalyzed by carbonic anhydrase II)
• Basolateral: HCO3- exits via Na+/HCO3- cotransporter (NBCe1) [39]

Organic Anion and Cation Secretion:

• OAT1, OAT3 (organic anion transporters): Secrete drugs, toxins, metabolites
• OCT2 (organic cation transporter): Secretes cationic drugs [40]

Loop of Henle:

Thick Ascending Limb (TAL):

• Na+/K+/2Cl- cotransporter (NKCC2): Actively transports 1 Na+, 1 K+, 2 Cl- from lumen to cell (furosemide target)
• K+ leaks back via ROMK channels, generating positive luminal potential
• Divalent cations (Mg2+, Ca2+) reabsorbed paracellularly driven by positive potential
• Impermeable to water (critical for countercurrent multiplication) [20]

Countercurrent Multiplication:

System generates medullary osmotic gradient from cortex (300 mOsm/kg) to inner medulla (1,200 mOsm/kg):

1. Descending limb: Water exits due to hypertonic medulla, concentrating tubular fluid
2. TAL: Na+, K+, Cl- reabsorbed without water, diluting tubular fluid and concentrating medulla
3. Vasa recta: Countercurrent exchangers maintaining gradient without washing out solutes
4. Collecting duct: Water reabsorption regulated by ADH, determining final urine concentration [41,42]

Key features:

• Single effect: Active transport in TAL adds ~200 mOsm/kg to medulla per pass
• Multiplied by countercurrent flow to reach 1,200 mOsm/kg
• Requires high blood flow to vasa recta but minimal washout due to countercurrent exchange [41,42]

Distal Nephron and Collecting Duct:

Principal Cells:

• Na+ reabsorption via ENaC (epithelial sodium channel) regulated by aldosterone (amiloride-sensitive)
• K+ secretion via ROMK channels (aldosterone-stimulated)
• Water reabsorption via aquaporin-2 (ADH-regulated) [23,24]

Intercalated Cells (Acid-Base Regulation):

Type A (Alpha) Intercalated Cells:

• H+ secretion via H+-ATPase and H+/K+-ATPase (acidifies urine)
• HCO3- reabsorption via Cl-/HCO3- exchanger (AE1) on basolateral membrane
• Predominant in acidosis [43]

Type B (Beta) Intercalated Cells:

• HCO3- secretion via Cl-/HCO3- exchanger (pendrin) on apical membrane
• H+ reabsorption (alkalinizes urine)
• Predominant in alkalosis [43]

Potassium Handling:

• PT: 65% of filtered K+ reabsorbed passively with water
• Loop of Henle: 25% reabsorbed in TAL via NKCC2
• DCT/Collecting Duct: Fine regulation - reabsorption or secretion depending on K+ balance and aldosterone
• Secretion: Principal cells secrete K+ in response to aldosterone, high K+ intake, alkalosis
• Reabsorption: Intercalated cells reabsorb K+ in K+ depletion [44]

Renin-Angiotensin-Aldosterone System (RAAS)

Renin Release:

Synthesized and released by juxtaglomerular cells in response to three primary stimuli:

1. Reduced renal perfusion pressure: Sensed by baroreceptors in afferent arteriole (most important)
2. Reduced NaCl delivery to macula densa: Via NKCC2 transporter activity
3. Sympathetic stimulation: β1-adrenergic receptor activation [45,46]

Renin-Angiotensin Cascade:

1. Renin acts on angiotensinogen (produced by liver): Angiotensinogen → Angiotensin I (decapeptide)

2. ACE (Angiotensin-Converting Enzyme) primarily in lung endothelium: Angiotensin I → Angiotensin II (octapeptide)

3. Angiotensin II actions:

   • Vascular smooth muscle: Potent vasoconstriction (increase MAP)
   • Adrenal cortex: Stimulates aldosterone synthesis
   • Brain: Thirst stimulation, ADH release, sympathetic outflow
   • Kidney: Preferential efferent arteriolar constriction (maintains GFR when RBF reduced), proximal Na+ reabsorption
   • Heart: Positive inotropy and hypertrophy (pathological) [45-47]

Aldosterone Synthesis and Action:

• Synthesized in zona glomerulosa of adrenal cortex
• Stimulated by Ang II, hyperkalemia, ACTH (minor)
• Acts on principal cells in collecting duct via mineralocorticoid receptor (MR)
• Induces ENaC and Na+/K+-ATPase expression → Na+ reabsorption, K+ secretion
• Also promotes H+ secretion (contributing to metabolic acidosis with hyperkalemia) [48,49]

Clinical Implications:

• ACE inhibitors: Reduce Ang II, decrease afterload, reduce intraglomerular pressure (renoprotective), cause hyperkalemia
• ARBs (Angiotensin receptor blockers): Block AT1 receptors without affecting bradykinin
• Aldosterone antagonists (spironolactone, eplerenone): Block MR, reduce Na+ reabsorption and K+ excretion
• Contraindications: Bilateral renal artery stenosis (depend on efferent constriction for GFR), hyperkalemia, pregnancy [36,50]

Antidiuretic Hormone (ADH / Vasopressin)

Synthesis and Release:

• Synthesized in supraoptic and paraventricular nuclei of hypothalamus
• Stored in posterior pituitary
• Released in response to:
  • Increased plasma osmolality (greater than 295 mOsm/kg) via osmoreceptors (primary stimulus)
  • Decreased blood volume/pressure detected by baroreceptors (volume depletion) [51,52]

Mechanism of Action:

• Binds to V2 receptors on basolateral membrane of principal cells in collecting duct
• Activates cAMP signaling pathway
• Induces translocation of aquaporin-2 water channels to apical membrane
• Increases water permeability, allowing water reabsorption down osmotic gradient
• Produces concentrated urine (up to 1,200 mOsm/kg) [51,53]

ADH Deficiency (Central Diabetes Insipidus):

• Polyuria (up to 10 L/day), polydipsia, hypernatremia
• Dilute urine (below 100 mOsm/kg)
• Treated with desmopressin (DDAVP) [54]

ADH Resistance (Nephrogenic Diabetes Insipidus):

• Similar symptoms but no response to DDAVP
• Causes: Lithium, hypercalcemia, hypokalemia, genetic mutations
• Treated with thiazide diuretics, low-sodium diet, NSAIDs [54,55]

Clinical Use in ICU:

• Vasopressin V1a receptor: Potent vasoconstriction (used in distributive shock)
• Vasopressin V2 receptor: Water retention (used in DI)
• Relative ADH deficiency in septic shock allows vasopressin administration at 0.03 U/min [56]

Renal Oxygenation

Renal Oxygen Consumption:

• Kidneys receive 20-25% of cardiac output but account for below 0.5% of body weight
• High oxygen consumption: 6-8 mL O2/100g/min (similar to brain)
• Reflects active Na+ transport (T1 = Na+ reabsorption / O2 consumption) [30,57]

Renal Oxygen Gradient:

• Cortex: Well-oxygenated (PaO2 40-50 mmHg)
• Outer medulla: Hypoxic (PaO2 10-20 mmHg) due to high oxygen consumption in TAL
• Inner medulla: Extremely hypoxic (PaO2 below 10 mmHg)

Medullary hypoxia results from:

• Countercurrent exchange reducing O2 delivery
• High oxygen demand in TAL for active Na+ transport
• Limited vascular supply to medulla [30,57]

Clinical Significance:

• Medulla operates near hypoxic threshold, susceptible to ischemic injury
• Sepsis, hypotension, and nephrotoxins exacerbate medullary hypoxia
• Diuretics reduce oxygen demand by inhibiting Na+ transport (renoprotective in some contexts)
• Radiocontrast agents increase medullary oxygen consumption (contrast nephropathy)
• ARF (acute renal failure) often begins in medulla due to oxygen supply-demand imbalance [30,57]

Acid-Base Homeostasis

Kidneys maintain plasma pH (7.35-7.45) by:

1. Reabsorbing filtered bicarbonate (4,500 mmol/day)
2. Generating new bicarbonate via ammoniagenesis
3. Excreting H+ as titratable acid and ammonium [58,59]

Bicarbonate Reabsorption (80-90% in Proximal Tubule):

Proximal Mechanism:

• Apical: H+ secreted via NHE3, combines with filtered HCO3- → CO2 + H2O (CA IV)
• Intracellular: CO2 + H2O → H2CO3 → H+ + HCO3- (CA II)
• Basolateral: HCO3- exits via NBCe1 (Na+/HCO3- cotransporter) [39]

Distal Mechanism (Type A Intercalated Cells):

• Apical: H+ secreted via H+-ATPase and H+/K+-ATPase
• Basolateral: HCO3- exits via AE1 (Cl-/HCO3- exchanger) [43]

Ammoniagenesis (Adaptive Component):

Process (Proximal Tubule):

• Glutamine → 2 NH4+ + 2 HCO3-
• NH4+ secreted into lumen (substituting for H+ on NHE3)
• HCO3- added to systemic circulation (new bicarbonate) [58]

Medullary Recycling:

• NH4+ reabsorbed in TAL via NKCC2 (substituting for K+)
• Accumulates in medullary interstitium
• Diffuses as NH3 into collecting duct lumen
• Secreted H+ binds NH3 → NH4+ (trapped and excreted) [58]

Adaptive Capacity:

• Can increase 5-10 fold in chronic acidosis
• Primary adaptive mechanism for acid excretion
• Impaired in renal failure leading to metabolic acidosis [58,59]

Titratable Acidity (Fixed Buffer System):

Process:

• Filtered phosphate (HPO4^2-) buffers secreted H+ → H2PO4-
• Each H+ excreted adds one HCO3- to blood
• Limited by filtered phosphate load (~40 mmol/day) [59]

Net Acid Excretion (NAE): NAE = (UNH4 × V) + (UTA × V) - (UHCO3 × V)

Where U = urine concentration, V = urine volume

Normal NAE = ~1 mEq/kg/day (matching endogenous acid production) [58,59]

Renal Tubular Acidosis:

Type 1 (Distal) RTA:

• Impaired H+ secretion in collecting duct
• Urine pH greater than 5.5 despite acidosis
• Causes: Autoimmune (Sjögren's), nephrocalcinosis, amphotericin B, genetic mutations [60]

Type 2 (Proximal) RTA:

• Impaired bicarbonate reabsorption in proximal tubule
• Bicarbonate wasting until plasma below 15 mmol/L
• Associated with Fanconi syndrome [60]

Type 4 (Hyperkalemic) RTA:

• Aldosterone deficiency or resistance
• Impaired K+ and H+ secretion
• Hypoaldosteronism, ACE inhibitors, NSAIDs [60]

Glomerular Filtration Rate Measurement

Serum Creatinine-Based GFR Estimation:

Creatinine characteristics:

• Endogenous waste product of muscle creatine metabolism
• Freely filtered, minimal secretion (below 10%)
• Not reabsorbed
• Production relatively constant but varies with muscle mass, age, sex, diet [61,62]

Limitations:

• Dependent on muscle mass (overestimates GFR in low muscle mass, underestimates in high muscle mass)
• Affected by diet (meat intake increases creatinine)
• Tubular secretion increases at low GFR (overestimates GFR)
• Non-GFR determinants (age, sex, race) incorporated into equations [61,62]

Creatinine-Based Equations:

Cockcroft-Gault (1976): Creatinine clearance (mL/min) = [(140 - age) × weight (kg)] / [72 × SCr (mg/dL)]

• Multiply by 0.85 for females
• Estimates creatinine clearance, not GFR
• Overestimates in obesity (uses total body weight) [62]

MDRD (Modification of Diet in Renal Disease) Study Equation (1999): GFR = 175 × SCr^-1.154 × age^-0.203 × (0.742 if female) × (1.21 if Black)

• Developed in CKD patients (GFR below 60 mL/min)
• Less accurate at higher GFR [63]

CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Equation (2009, 2021): More accurate across GFR range

• Incorporates creatinine, age, sex, race (2021 version removes race coefficient)
• Currently recommended by KDIGO guidelines [64]

Cystatin C-Based GFR Estimation:

Cystatin C characteristics:

• Low molecular weight cysteine protease inhibitor (13 kDa)
• Freely filtered, reabsorbed and metabolized in proximal tubule (not secreted)
• Produced at constant rate by all nucleated cells
• Less influenced by muscle mass, age, sex, diet [65,66]

Advantages:

• Independent of muscle mass
• Less affected by diet
• Better predictor of outcomes (mortality, cardiovascular events)
• More accurate detection of early CKD [65,66]

Disadvantages:

• More expensive than creatinine
• Affected by thyroid function, inflammation, corticosteroids
• Less widely available [65,66]

Combined Equations: CKD-EPI Creatinine-Cystatin C Equation:

• Uses both biomarkers
• More accurate than either alone
• Recommended when precision critical (e.g., drug dosing, transplant evaluation) [64,67]

Creatinine vs Cystatin C Comparison:

Clinical Applications in ICU:

• Baseline GFR assessment for drug dosing
• Detection of AKI (KDIGO criteria: ≥26.5 μmol/L increase in 48h or ≥50% increase in 7 days)
• RRT initiation decisions (KDIGO Stage 3 AKI)
• Nephrotoxic medication monitoring (aminoglycosides, vancomycin, contrast) [61,68]

Alternative GFR Measurement:

Iohexol Clearance:

• Exogenous contrast marker (freely filtered, not secreted)
• Gold standard for GFR measurement
• Single plasma sample method convenient
• Used when creatinine unreliable (extremes of muscle mass, rapid GFR changes) [69]

Inulin Clearance:

• True gold standard (freely filtered, not secreted, reabsorbed, or metabolized)
• Requires continuous infusion and urine collection
• Research use only, not clinically practical [70]

---

Clinical Pearls

Exam Detail: CICM Fellowship Exam Focus:

• Autoregulation: Myogenic (1-3 sec) vs TGF (10-20 sec) mechanisms, pressure range 80-170 mmHg, clinical consequences of impaired autoregulation (diabetes, CKD)

• RAAS in Critical Illness: Ang II maintains MAP via vasoconstriction, efferent arteriolar constriction preserves GFR, aldosterone causes Na+ retention and K+ loss

• SGLT2 Inhibitors: Increase NaCl delivery to macula densa → activate TGF → afferent vasoconstriction → reduce intraglomerular pressure → renoprotective in diabetes, reduce hyperfiltration

• NSAIDs in ICU: Inhibit prostaglandin-mediated afferent arteriolar vasodilation → reduce RBF in volume depletion, cause AKI, especially in CKD, elderly, hypovolemia

• ACE Inhibitors in Renal Artery Stenosis: Rely on efferent arteriolar constriction for GFR → ACE inhibition dilates efferent → reduces intraglomerular pressure → decreases GFR, contraindicated in bilateral RAS

• ADH in Septic Shock: Relative ADH deficiency allows vasopressin use at 0.03 U/min, V1a-mediated vasoconstriction, sparing α-adrenergic agonists, less tachycardia

• Medullary Hypoxia: Cortex PaO2 40-50 mmHg, medulla PaO2 10-20 mmHg, high Na+ transport demand, susceptibility to ischemic injury, mechanism of contrast nephropathy

• Bicarbonate Wasting: Type 2 RTA - proximal bicarbonate reabsorption impaired, bicarbonateuria until threshold reached, associated with Fanconi syndrome (phosphate, glucose, amino acid wasting)

• Ammoniagenesis: Adaptive acid excretion, can increase 5-10 fold, impaired in CKD leading to metabolic acidosis, NH4+ trapping in collecting duct

• GFR Estimation: Creatinine (muscle-dependent, age/sex/race affected) vs cystatin C (muscle-independent, more accurate), CKD-EPI recommended, combined equation most accurate

Clinical Pearl: ICU Practical Tips:

• AKI Prevention in Contrast-Induced Nephropathy: Hydration (1 mL/kg/hr isotonic saline before and after contrast), NAC 600 mg PO BID, consider pre-procedural diuretics to reduce medullary oxygen consumption

• Creatinine Interpretation in ICU: Acute changes more significant than absolute values, consider muscle wasting (overestimates GFR), fluid overload (dilution), delayed rise after injury

• Potassium Management in AKI: Monitor q6h, consider renal replacement therapy for K+ greater than 6.5 mmol/L with ECG changes, calcium gluconate stabilizes membrane, insulin-glucose shifts K+ intracellularly

• RAAS Modulation: ACE inhibitors reduce intraglomerular pressure (renoprotective), but stop if AKI suspected, hold in hypotension, restart when stable

• Sepsis-Associated AKI: Multifactorial - hypoperfusion, inflammation, microcirculatory dysfunction, nephrotoxic drugs, consider early RRT if refractory metabolic acidosis, volume overload, or uremia

---

Assessment

SAQ Practice Questions

SAQ 1: Renal Autoregulation and Clinical Implications (15 marks)

Question: A 68-year-old man with hypertension and type 2 diabetes mellitus is admitted with community-acquired pneumonia requiring ICU admission. His blood pressure is 165/95 mmHg, heart rate 95/min, temperature 38.5°C. Serum creatinine is 95 μmol/L (baseline 75 μmol/L 2 months ago). His current medications include ramipril 5 mg daily.

a) Describe the physiological mechanisms of renal autoregulation, including the pressure range over which it operates. (5 marks)

b) Explain how diabetes mellitus and hypertension impair these mechanisms, and the clinical consequences. (4 marks)

c) Discuss the pharmacological effects of ramipril on renal haemodynamics, and whether continuation or cessation is appropriate in this clinical context. (3 marks)

d) List three other medications commonly used in critically ill patients that can interfere with renal autoregulation and their mechanisms of action. (3 marks)

---

Model Answer:

a) Renal Autoregulation Mechanisms (5 marks)

Renal autoregulation maintains constant renal blood flow (RBF) and glomerular filtration rate (GFR) across mean arterial pressure range of 80-170 mmHg. Two primary mechanisms operate: [31,32]

Myogenic Mechanism (1 mark):

• Acts within 1-3 seconds
• Afferent arteriole smooth muscle senses wall stretch from increased pressure
• Stretch activates Ca2+ channels → depolarization → vasoconstriction
• Decreased pressure causes vasodilation
• Protects glomeruli from hypertensive injury [32,33]

Tubuloglomerular Feedback (TGF) (1 mark):

• Acts within 10-20 seconds
• Macula densa cells in distal thick ascending limb sense NaCl delivery via NKCC2 transporter
• Increased NaCl delivery (indicating high GFR) → adenosine/ATP release → A1 receptor activation on afferent arteriole → vasoconstriction
• Decreased NaCl delivery → renin release → Angiotensin II → efferent arteriole constriction → maintains GFR
• Operates as negative feedback loop [34,35]

Integration (1 mark):

• Myogenic mechanism handles high-frequency pressure fluctuations
• TGF fine-tunes GFR based on tubular flow
• Both constrict afferent arteriole during increased pressure
• Synergistic action provides robust protection [32,35]

Pressure Range (1 mark):

• Operates from mean arterial pressure 80-170 mmHg
• Below 80 mmHg: Autoregulation fails, RBF and GFR fall linearly with pressure
• Above 170 mmHg: Pressure transmitted to glomeruli, causing injury [31,32]

Key Structures (1 mark):

• Afferent arteriole: Primary regulator (both mechanisms)
• Efferent arteriole: Regulated by Ang II (TGF)
• Juxtaglomerular apparatus: Macula densa, JG cells, extraglomerular mesangial cells [25]

b) Diabetes and Hypertension Effects on Autoregulation (4 marks)

Diabetes Mellitus Impairment (2 marks):

• Hyperfiltration early: Increased GFR due to afferent arteriolar dilatation
• Glomerular hypertension: Increased intraglomerular pressure
• Endothelial dysfunction: Impaired vasodilator responses
• Advanced glycation end-products: Vascular stiffness
• Podocyte injury: Glomerular filtration barrier damage
• Result: Shifted autoregulatory curve (higher minimum pressure), reduced capacity, increased susceptibility to hypertensive injury → glomerulosclerosis [36,37]

Hypertension Impairment (2 marks):

• Chronic systemic hypertension: Vascular remodeling, hypertrophy
• Afferent arteriolar hyalinosis: Impaired myogenic response
• Reduced compliance: Stiffer vessels
• Leftward shift: Autoregulation operates at higher pressures
• Consequences: Glomerular capillary damage, proteinuria, progressive CKD
• Clinical: Exacerbates diabetic nephropathy, accelerates decline [36,37]

Combined Effects:

• Synergistic damage: Diabetes + hypertension = worse than either alone
• Proteinuria: Marker of glomerular injury
• Progressive GFR decline: Due to nephron loss, sclerosis
• Treatment goal: Tight BP control (below 130/80 mmHg), ACE inhibitors/ARBs renoprotective [36,50]

c) Ramipril Effects and Decision (3 marks)

Ramipril Pharmacological Actions (1.5 marks):

• ACE inhibitor: Inhibits conversion of Angiotensin I → Angiotensin II
• Renal effects:
  • Reduces Ang II-mediated efferent arteriolar constriction → decreased intraglomerular pressure (renoprotective)
  • Preferential efferent vasodilation → reduces filtration fraction
  • Reduces proteinuria (beneficial in diabetic nephropathy)
  • May decrease GFR slightly (reflects reduced intraglomerular pressure)
• Systemic effects: Reduces systemic vascular resistance, afterload reduction [36,50]

Clinical Decision (1.5 marks):

Current context:

• Elevated BP (165/95), possible volume depletion from fever/infection
• Mild creatinine rise (75 → 95 μmol/L)
• Patient on chronic ACE inhibitor for hypertension/diabetic nephropathy

Recommendation:

• Hold ramipril temporarily
• Reasons: Risk of AKI from hypotension, volume depletion, sepsis, possible bilateral renal artery stenosis
• Monitor renal function q24h, volume status, BP
• Restart when clinically stable (euvolemic, normotensive, improving infection)
• Consider continuing if well-tolerated and only mild AKI (KDIGO Stage 1), but most would hold in acute severe illness [36,50]

d) Other Medications Affecting Renal Autoregulation (3 marks)

1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): (1 mark)

   • Inhibit prostaglandin synthesis (COX-1, COX-2)
   • Prostaglandins mediate afferent arteriolar vasodilation, particularly in volume depletion
   • NSAID effect: Unopposed vasoconstriction → reduced RBF → AKI
   • Risk increased in: Hypovolemia, CKD, elderly, concomitant ACE inhibitors/ARBs [36]

2. Angiotensin Receptor Blockers (ARBs): (1 mark)

   • Block AT1 receptors, similar effects to ACE inhibitors
   • Reduce Ang II-mediated efferent arteriole constriction
   • Decrease intraglomerular pressure (renoprotective)
   • May reduce GFR, risk in bilateral renal artery stenosis [36,50]

3. Calcium Channel Blockers: (1 mark)

   • Dihydropyridines (e.g., nifedipine): Afferent arteriolar dilatation → may increase intraglomerular pressure (less renoprotective than ACE inhibitors)
   • Non-dihydropyridines (e.g., diltiazem, verapamil): Less afferent dilation
   • Generally safe in CKD, but not first-line for renoprotection in diabetic nephropathy [36]

Other acceptable answers:

• SGLT2 inhibitors: Increase NaCl delivery to macula densa → activate TGF → afferent vasoconstriction → renoprotective [36,37]
• Vasopressin analogues: V1a-mediated vasoconstriction may reduce renal blood flow
• Catecholamines: α-mediated renal vasoconstriction, β1-mediated renin release

---

SAQ 2: Renal Acid-Base Physiology (15 marks)

Question: A 45-year-old man with a history of alcohol dependence presents with recurrent vomiting for 5 days. His arterial blood gas shows pH 7.28, PaCO2 30 mmHg, HCO3- 14 mmol/L. Serum sodium 135 mmol/L, potassium 2.8 mmol/L, chloride 105 mmol/L, creatinine 98 μmol/L. Urinalysis shows pH 6.5.

a) Describe the three principal mechanisms by which the kidney regulates acid-base homeostasis. (5 marks)

b) Explain the physiological basis of the hypokalaemia in this patient, including the relationship between potassium and acid-base balance. (4 marks)

c) Discuss the normal renal handling of ammonium, and how this process is adapted in chronic metabolic acidosis. (3 marks)

d) Outline the classification and pathophysiology of renal tubular acidosis. (3 marks)

---

Model Answer:

a) Renal Acid-Base Homeostasis Mechanisms (5 marks)

Kidneys maintain plasma pH (7.35-7.45) through three integrated processes: [58,59]

1. Bicarbonate Reabsorption (2 marks):

• Filtered bicarbonate: ~4,500 mmol/day, virtually all must be reabsorbed
• Proximal tubule: Reabsorbs 80-90% of filtered bicarbonate
  • "Apical: H+ secreted via NHE3 (Na+/H+ exchanger)"
  • H+ combines with filtered HCO3- → CO2 + H2O (catalyzed by carbonic anhydrase IV)
  • "Intracellular: CO2 + H2O → H2CO3 → H+ + HCO3- (catalyzed by CA II)"
  • "Basolateral: HCO3- exits via NBCe1 (Na+/HCO3- cotransporter)"
• Distal nephron: Remaining bicarbonate reabsorbed via Type A intercalated cells
  • "Apical: H+ secreted via H+-ATPase and H+/K+-ATPase"
  • "Basolateral: HCO3- exits via AE1 (Cl-/HCO3- exchanger) [39,43]"

2. Titratable Acid Excretion (1 mark):

• Process: Filtered phosphate buffers secreted H+
• Filtered HPO4^2- + H+ (secreted) → H2PO4-
• Each H+ excreted adds one HCO3- to blood
• Limited by filtered phosphate load (~40 mmol/day)
• Contributes ~40-60 mmol H+ excretion/day in normal acid-base state [59]

3. Ammoniagenesis and Ammonium Excretion (2 marks):

• Most adaptive and significant component of acid excretion
• Ammoniagenesis (proximal tubule): Glutamine → 2 NH4+ + 2 HCO3-
  • NH4+ secreted into lumen (substituting for H+ on NHE3)
  • HCO3- added to systemic circulation (new bicarbonate)
• Medullary recycling: NH4+ reabsorbed in TAL via NKCC2, accumulates in medulla
• Collecting duct: NH3 diffuses from interstitium, secreted H+ binds NH3 → NH4+ (trapped and excreted)
• Can increase 5-10 fold in chronic acidosis
• Primary adaptive mechanism, major contributor to net acid excretion [58]

Net Acid Excretion: NAE = (UNH4 × V) + (UTA × V) - (UHCO3 × V) Normal NAE ~1 mEq/kg/day (matches endogenous acid production) [58,59]

b) Hypokalaemia and Acid-Base Relationship (4 marks)

Patient's Acid-Base Picture (1 mark):

• pH 7.28 (acidemia)
• PaCO2 30 mmHg (appropriate compensation)
• HCO3- 14 mmol/L (metabolic acidosis)
• Anion gap = Na+ - (Cl- + HCO3-) = 135 - (105 + 14) = 16 (normal)
• Diagnosis: Normal anion gap metabolic acidosis with vomiting-related alkalosis (mixed disorder) → predominantly metabolic acidosis

Mechanisms of Hypokalaemia in Vomiting (3 marks):

1. Gastrointestinal Potassium Loss (1 mark):

• Gastric secretions contain significant potassium (5-10 mmol/L)
• Profuse vomiting causes direct K+ loss
• Estimated K+ loss: 10-40 mmol/day in significant vomiting [44]

2. Renal Potassium Loss (2 marks):

Metabolic Alkalosis Mechanism:

• Vomiting causes loss of gastric acid (HCl) → metabolic alkalosis (elevated HCO3-)
• Alkalosis causes:
  • "Cellular shift: K+ moves into cells in exchange for H+ (maintain electroneutrality)"
  • "Renal adaptation: Kidneys attempt to excrete excess HCO3- by secreting H+ (via Type A intercalated cells)"
  • H+ secretion requires maintenance of electroneutrality → K+ secreted in exchange

Volume Depletion Mechanism:

• Vomiting causes volume depletion → activates RAAS
• Aldosterone stimulates Na+ reabsorption and K+ secretion in principal cells
• Hyperaldosteronism (secondary) → increased urinary K+ excretion [44,48,49]

Cellular Shift:

• Alkalosis: H+ moves out of cells, K+ moves into cells (transcellular shift)
• β2-adrenergic stimulation: Promotes K+ entry into cells (may occur with stress)

Hypokalaemia Effects on Acid-Base (bidirectional):

• Hypokalaemia causes metabolic alkalosis (alkalosis worsens hypokalaemia)
• Mechanism: Hypokalaemia → renal K+ conservation → H+ secretion (Type B intercalated cells inhibited, Type A stimulated) → alkalosis
• Vicious cycle: Alkalosis → K+ loss → worsening alkalosis [44,59]

c) Ammonium Handling and Adaptation (3 marks)

Normal Ammonium Handling (2 marks):

Ammoniagenesis (Proximal Tubule):

• Glutamine metabolism: Glutamine → 2 NH4+ + 2 HCO3-
• NH4+ secreted into lumen via NHE3 (substituting for H+)
• HCO3- added to blood (new bicarbonate generation)
• Rate controlled by acid-base status, glutamine availability [58]

Medullary Recycling:

• NH4+ reabsorbed in thick ascending limb via NKCC2 (substituting for K+)
• Accumulates in medullary interstitium (concentration ~200-400 mmol/L)
• Creates gradient for NH3 diffusion into collecting duct
• Prevents urinary NH4+ loss [58]

Collecting Duct Trapping:

• NH3 diffuses from interstitium into lumen (lipid-soluble, crosses membrane)
• Type A intercalated cells secrete H+ via H+-ATPase
• H+ + NH3 → NH4+ (charged, trapped in lumen)
• NH4+ excreted in urine, each NH4+ adds one HCO3- to blood [58]

Adaptation in Chronic Metabolic Acidosis (1 mark):

• Increased ammoniagenesis: Glutaminase enzyme upregulated 5-10 fold
• Enhanced medullary accumulation: Increased NH4+ transport via NKCC2
• Increased NH3 production: More NH4+ → NH3 + H+ in lumen
• Primary adaptive response: Ammonium excretion increases from 30 mmol/day to 200-300 mmol/day
• Limits: Impaired in CKD, interstitial nephritis, obstructive uropathy
• Clinical significance: If impaired, leads to chronic metabolic acidosis despite normal bicarbonate reabsorption [58,59]

d) Renal Tubular Acidosis Classification (3 marks)

Type 1 (Distal) RTA (1 mark):

• Pathophysiology: Impaired H+ secretion in collecting duct (distal nephron)
• Mechanisms: H+-ATPase pump defect, back-leak of H+, abnormal voltage
• Clinical features: Urine pH greater than 5.5 despite systemic acidosis, hypokalaemia, nephrocalcinosis, renal stones
• Causes: Autoimmune (Sjögren's, SLE), inherited mutations, nephrocalcinosis, amphotericin B, obstructive uropathy
• Treatment: Alkali therapy (NaHCO3, Shohl's solution), potassium repletion, thiazides for hypercalciuria [60]

Type 2 (Proximal) RTA (1 mark):

• Pathophysiology: Impaired bicarbonate reabsorption in proximal tubule
• Mechanism: Defect in NHE3, NBCe1, or carbonic anhydrase II
• Clinical features: Bicarbonate wasting in urine until plasma HCO3- below 15 mmol/L (reduced reabsorption threshold), normal acidification capacity (can acidify urine), Fanconi syndrome (phosphate, glucose, amino acid wasting)
• Causes: Inherited mutations, multiple myeloma (light chain toxicity), heavy metals, acetazolamide, Wilson's disease
• Treatment: Thiazides (induce mild volume depletion, enhance proximal reabsorption), alkali therapy, treat underlying cause [60]

Type 4 (Hyperkalemic) RTA (1 mark):

• Pathophysiology: Aldosterone deficiency or resistance
• Mechanism: Impaired K+ and H+ secretion in principal cells (mineralocorticoid receptor defect, ENaC defect, aldosterone deficiency)
• Clinical features: Hyperkalaemia, mild metabolic acidosis, urine pH below 5.5 (can acidify), reduced NH4+ excretion
• Causes: Hypoaldosteronism (Addison's disease, selective aldosterone deficiency), ACE inhibitors/ARBs, NSAIDs, potassium-sparing diuretics, diabetes (hyporeninemic hypoaldosteronism), interstitial nephritis
• Treatment: Fludrocortisone (mineralocorticoid replacement), furosemide (promote K+ excretion), dietary K+ restriction, avoid ACE inhibitors/ARBs if possible [60]

Type 3 RTA:

• Rare, combination of Type 1 and Type 2 features
• Usually due to carbonic anhydrase II deficiency

---

Viva Practice Questions

Viva 1: Renal Physiology and Critical Illness (20 marks)

Examiner: "Discuss the physiological adaptations that occur in the kidney during septic shock, and explain how these contribute to the development of acute kidney injury."

---

Model Answer:

Candidate: "Thank you. I'll discuss the renal haemodynamic, cellular, and tubular adaptations in septic shock and their contribution to AKI."

1. Renal Haemodynamic Changes (6 marks):

Early Septic Shock (Hyperdynamic Phase):

• Increased Cardiac Output: Compensatory response to distributive shock
• Renal Blood Flow: Initially may be maintained or increased due to hyperdynamic circulation
• Redistribution: Cortical blood flow may increase, but medullary perfusion may decrease due to shunting
• Vasodilation: Nitric oxide (NO) overproduction causes systemic and renal vasodilation
• Autoregulation Impairment: Endothelial dysfunction, inflammatory mediators disrupt myogenic and TGF mechanisms
• Consequences: Despite normal or increased global RBF, medullary hypoxia occurs due to shunting and maldistribution [30,57]

Late Septic Shock (Hypodynamic Phase):

• Decreased Cardiac Output: Myocardial depression, persistent vasodilation
• Reduced Renal Perfusion Pressure: Mean arterial pressure falls below autoregulatory range (below 80 mmHg)
• Vasoconstriction: Sympathetic activation, catecholamines cause renal vasoconstriction
• Microcirculatory Dysfunction: Capillary plugging, endothelial swelling, impaired oxygen extraction
• Ischaemia: Cortical and medullary ischaemia, tubular injury [30,57]

2. Cellular and Molecular Mechanisms (6 marks):

Inflammatory Cascade:

• Cytokines: TNF-α, IL-1β, IL-6 released systemically and locally
• Endothelial Activation: Upregulation of adhesion molecules, leukocyte recruitment
• Oxidative Stress: Reactive oxygen species (ROS) damage tubular cells and mitochondria
• Complement Activation: Alternative pathway activated, causing direct tubular injury [57,61]

Mitochondrial Dysfunction:

• Energy Failure: Impaired oxidative phosphorylation, reduced ATP production
• Apoptosis: Programmed cell death induced by inflammatory mediators, oxidative stress
• Necrosis: Severe ATP depletion leads to cell death, tubular necrosis
• Autophagy: Impaired cellular cleanup mechanism, accumulation of damaged organelles [57]

Tubular Cell Injury:

• Loss of Polarity: Redistribution of transporters, impaired solute handling
• Cytoskeletal Disruption: Disruption of actin filaments, loss of brush border in proximal tubule
• Cell Detachment: Cells detach from basement membrane, forming casts that obstruct tubules
• Back-Leak: Glomerular filtrate leaks back into interstitium through damaged epithelium [57,61]

3. Tubular Adaptations and Dysfunction (4 marks):

Proximal Tubule:

• Ischaemic Injury: Most vulnerable due to high oxygen demand, first segment affected
• Sodium Reabsorption Impairment: Decreased Na+/K+-ATPase activity, reduced NHE3 function
• Bicarbonate Wasting: Impaired H+ secretion, proximal RTA picture
• Fanconi Syndrome: Generalised proximal dysfunction (glucose, phosphate, amino acid wasting) in severe cases [61]

Thick Ascending Limb:

• Countercurrent Multiplier Impairment: Disruption of medullary gradient
• Concentrating Defect: Inability to concentrate urine, polyuria
• Diuretic Resistance: Impaired response to loop diuretics due to reduced delivery [20,41]

Collecting Duct:

• ADH Resistance: Impaired water reabsorption, nephrogenic DI
• Potassium Handling: Dysregulated K+ secretion, hyperkalaemia or hypokalaemia
• Acid-Base: Impaired ammonium excretion, metabolic acidosis [51,54]

4. Clinical Manifestations and Diagnosis (2 marks):

AKI Definition (KDIGO Criteria):

• Serum creatinine increase ≥26.5 μmol/L within 48 hours
• OR serum creatinine increase ≥1.5 times baseline within 7 days
• OR urine output below 0.5 mL/kg/hr for 6 hours [61,68]

Biomarkers:

• NGAL (Neutrophil Gelatinase-Associated Lipocalin): Early marker of tubular injury (within 2-6 hours)
• KIM-1 (Kidney Injury Molecule-1): Proximal tubule injury marker
• IL-18: Proximal tubule injury, ischemia-reperfusion injury
• Cystatin C: Earlier rise than creatinine, less affected by muscle mass [61,65]

Urinary Findings:

• Granular casts (muddy brown casts) - pathognomonic for ATN
• Renal tubular epithelial cells
• Low urine sodium (below 20 mmol/L) in pre-renal, high (greater than 40 mmol/L) in ATN
• Fractional excretion of sodium (FENa) below 1% pre-renal, greater than 2% ATN [61]

5. Management Principles (2 marks):

Prevention:

• Adequate fluid resuscitation (guided by lactate, ScvO2, clinical assessment)
• Avoid nephrotoxins (NSAIDs, aminoglycosides, radiocontrast) if possible
• Maintain MAP greater than 65 mmHg (consider higher in chronic hypertensive patients to protect autoregulation)
• Consider renal protective strategies (low-dose dopamine? - no evidence; fenoldopam - mixed results) [61]

Treatment:

• Remove nephrotoxins
• Optimize haemodynamics (fluids, vasopressors)
• Consider early RRT in: refractory metabolic acidosis, hyperkalaemia, volume overload, uremia
• No specific pharmacological therapy proven (no benefit from diuretics for prevention, dopamine not effective)
• Ongoing research: Mesenchymal stem cells, specific anti-inflammatory agents [61,68]

Summary: Sepsis causes AKI through a complex interplay of haemodynamic changes (redistribution, impaired autoregulation), cellular injury (inflammation, oxidative stress, mitochondrial dysfunction), and tubular dysfunction (impaired transport, cast formation). The result is decreased GFR, impaired concentrating ability, electrolyte disturbances, and metabolic acidosis. Prevention focuses on optimising perfusion and avoiding nephrotoxins, while treatment involves RRT for refractory complications."

---

Viva 2: RAAS System and Pharmacology (20 marks)

Examiner: "Explain the renin-angiotensin-aldosterone system in detail, including its components, physiological actions, and the effects of pharmacological manipulation. Discuss specifically the use of ACE inhibitors in critical care, including their benefits and risks."

---

Model Answer:

Candidate: "I'll discuss the RAAS components, physiological actions, and then focus on ACE inhibitors in critical care with their benefits and risks."

1. RAAS Components and Physiology (8 marks):

Renin (3 marks):

• Synthesis: Juxtaglomerular cells in afferent arteriole
• Storage: Stored in granules within JG cells
• Release Stimuli:
  1. Reduced renal perfusion pressure (baroreceptors in afferent arteriole) - PRIMARY
  2. Reduced NaCl delivery to macula densa (via NKCC2 transporter)
  3. Sympathetic stimulation (β1-adrenergic receptors)
  4. Low NaCl intake, diuretic use, volume depletion [45,46]

Angiotensinogen:

• Source: Liver (constant synthesis)
• Structure: Glycoprotein, 452 amino acids
• Function: Substrate for renin [45]

Angiotensin I:

• Formation: Renin cleaves angiotensinogen → Ang I (decapeptide)
• Activity: Minimal biological activity [45]

Angiotensin-Converting Enzyme (ACE):

• Location: Primarily lung endothelium (also kidney, brain, endothelium)
• Function: Cleaves Ang I → Ang II (octapeptide)
• Other Substrates: Also degrades bradykinin (explains cough with ACE inhibitors) [45,46]

Angiotensin II (3 marks):

• Key Actions:
  • "Vascular: Potent vasoconstriction (increase systemic vascular resistance, MAP)"
  • "Renal: Preferential efferent arteriolar constriction (maintains GFR when RBF reduced), proximal Na+ reabsorption"
  • "Adrenal: Stimulates aldosterone synthesis (zona glomerulosa)"
  • "Brain: Thirst stimulation, ADH release, sympathetic outflow"
  • "Heart: Positive inotropy, hypertrophy (pathological) [45-47]"

Aldosterone (2 marks):

• Synthesis: Zona glomerulosa of adrenal cortex
• Stimuli: Ang II (primary), hyperkalaemia, ACTH (minor)
• Actions: Binds mineralocorticoid receptor on principal cells → upregulates ENaC and Na+/K+-ATPase → Na+ reabsorption, K+ secretion
• Additional Effects: H+ secretion (contributes to metabolic acidosis), fibrosis in heart and kidney [48,49]

2. Pharmacological Manipulation of RAAS (4 marks):

ACE Inhibitors (2 marks):

• Mechanism: Inhibit ACE → reduce Ang II, increase bradykinin
• Effects:
  • Reduced systemic vascular resistance (afterload reduction)
  • Reduced intraglomerular pressure (efferent arteriole dilation)
  • Decreased aldosterone → Na+ excretion, K+ retention
  • Reduced proteinuria, renoprotective
• Examples: Ramipril, enalapril, captopril, lisinopril
• Side Effects: Cough (bradykinin), hyperkalaemia, AKI (in bilateral RAS), angioedema [36,50]

Angiotensin Receptor Blockers (ARBs) (1 mark):

• Mechanism: Block AT1 receptors (competitive, competitive insurmountable)
• Effects: Similar to ACE inhibitors but without bradykinin effects (no cough)
• Examples: Losartan, valsartan, candesartan, telmisartan
• Side Effects: Hyperkalaemia, AKI, less cough than ACE inhibitors [36,50]

Aldosterone Antagonists (1 mark):

• Mechanism: Block mineralocorticoid receptor
• Effects: Reduce Na+ reabsorption, increase K+ excretion
• Examples: Spironolactone (non-selective), eplerenone (selective), finerenone (non-steroidal)
• Side Effects: Hyperkalaemia, gynaecomastia (spironolactone), antiandrogenic effects (spironolactone) [48,50]

3. ACE Inhibitors in Critical Care (4 marks):

Benefits (2 marks):

Cardiovascular Protection:

• Heart Failure: Reduce afterload, improve cardiac output, reduce mortality
• Post-MI: Remodeling prevention, reduced mortality, reduced heart failure development
• Renoprotection: Reduce intraglomerular pressure, slow CKD progression, reduce proteinuria in diabetic nephropathy
• Atrial Fibrillation: May reduce AF recurrence post-cardioversion [36,50]

Sepsis and ARDS:

• Microvascular Protection: May improve microcirculation, endothelial function
• Anti-inflammatory: Reduce cytokine production, modulate immune response
• Evidence: Mixed - some studies suggest reduced AKI incidence, others show no benefit

Chronic Kidney Disease:

• Diabetic Nephropathy: First-line for renoprotection, slow progression to ESRD
• Proteinuria: Significant reduction, independent of blood pressure effect
• Mechanism: Reduced intraglomerular pressure, antifibrotic effects [36,50]

Risks and Contraindications (2 marks):

Acute Kidney Injury (1 mark):

• Mechanism: Reduce intraglomerular pressure → decreased GFR
• Risk Groups: Hypovolemia, bilateral renal artery stenosis, CKD, elderly
• Management: Hold ACE inhibitors in acute illness, AKI, hypovolemia, hypotension
• Monitoring: Check creatinine and K+ 5-7 days after initiation/dose change, monitor closely in ICU [36,50]

Hyperkalaemia (1 mark):

• Mechanism: Reduced aldosterone effect → reduced K+ excretion
• Risk Groups: CKD, diabetes, potassium supplements, NSAIDs, potassium-sparing diuretics
• Management: Monitor K+ regularly, restrict dietary potassium, consider potassium binders (patiromer, sodium zirconium cyclosilicate) if chronic use [50]

Other Contraindications:

• Bilateral renal artery stenosis (absolute)
• Pregnancy (teratogenic - fetal renal dysplasia)
• Angioedema (relative - may cross-react)
• Severe hypotension [36,50]

4. Practical Considerations in ICU (4 marks):

Initiation (2 marks):

Timing:

• Avoid starting in acute severe illness, hypovolemia, or established AKI
• Start in stable patients for chronic conditions (heart failure, CKD)
• Consider restarting when clinically stable after critical illness

Dosing (1 mark):

• Start low, go slow (e.g., ramipril 1.25-2.5 mg daily)
• Titrate based on blood pressure response, renal function, potassium
• Adjust for renal function (reduce dose in moderate-severe CKD)

Monitoring (1 mark):

• Renal function: Creatinine, urea (expect small rise ≤30% acceptable, stop if greater than 30%)
• Potassium: Baseline, 5-7 days after initiation/dose change, regularly with other nephrotoxins
• Blood pressure: Monitor for hypotension, reduce dose if MAP below 65 mmHg
• Urine output: Monitor for oliguria, AKI [36,50]

5. Alternative Agents and Future Directions (2 marks):

ARNIs (Angiotensin Receptor-Neprilysin Inhibitors):

• Sacubitril/valsartan (Entresto)
• Combines ARB (valsartan) with neprilysin inhibitor (sacubitril)
• Increases natriuretic peptides (BNP, CNP) → vasodilation, natriuresis
• Superior to ACE inhibitors in heart failure (PARADIGM-HF trial)
• Consider in chronic heart failure, not acute critical care [50]

Renin Inhibitors:

• Aliskiren
• Direct renin inhibition
• Less commonly used, similar effects to ACE inhibitors
• Avoid with ACE inhibitors/ARBs (increased adverse effects) [36]

SGLT2 Inhibitors:

• Empagliflozin, dapagliflozin, canagliflozin
• Increase NaCl delivery to macula densa → activate TGF → afferent vasoconstriction
• Reduce intraglomerular pressure, renoprotective in diabetes
• Cardiovascular benefits, heart failure hospitalisation reduction
• Consider in CKD with proteinuria, heart failure, diabetes [36,37]

Summary: The RAAS system is crucial for blood pressure and fluid homeostasis. ACE inhibitors are valuable in chronic conditions (heart failure, CKD, diabetic nephropathy) for their renoprotective and cardiovascular benefits. In critical care, they should generally be held during acute illness due to risks of AKI and hyperkalaemia. Alternative agents like ARBs, SGLT2 inhibitors, and ARNIs offer additional options for chronic management."

---

References

1. Brenner BM, Rector FC. Brenner & Rector's The Kidney. 11th ed. Philadelphia: Elsevier; 2023.

2. Hall JE. Guyton and Hall Textbook of Medical Physiology. 14th ed. Philadelphia: Elsevier; 2020.

3. Boron WF, Boulpaep EL. Medical Physiology. 3rd ed. Philadelphia: Elsevier; 2017.

4. Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders. 6th ed. New York: McGraw-Hill; 2015.

5. Lote CJ. Principles of Renal Physiology. 5th ed. Dordrecht: Springer; 2012.

6. Palmer BF, Alpern RJ. Integrated renal physiology. Clin J Am Soc Nephrol. 2010;5(7):1255-1263. PMID: 20489344.

7. Wilcox CS. Regulation of renal blood flow by plasma chloride. J Clin Invest. 1983;71(3):726-735. PMID: 6300383.

8. Schnermann J, Briggs JP. Function of the juxtaglomerular apparatus: control of glomerular hemodynamics and renin secretion. In: Seldin DW, Giebisch G, eds. The Kidney: Physiology and Pathophysiology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.

9. Giebisch G, Windhager E. Renal tubular transfer of sodium, chloride, and potassium. Am J Med. 1964;36:643-669. PMID: 14158823.

10. Vallon V, Thomson SC. Renal function in chronic disease: impact of diabetes and obesity. J Nephrol. 2020;33(5):905-915. PMID: 32106865.

11. Puelles VG, Cullen-McEwen LA, Eadon J, et al. The podocyte number predicts renal disease severity in Fabry's disease. Kidney Int. 2014;85(5):1062-1071. PMID: 24177095.

12. Bertram JF, Young RJ, Hoy WE. Count and classification of glomeruli in the adult, human kidney. J Am Soc Nephrol. 2011;22(2):373-376. PMID: 21209388.

13. Haraldsson B, Nyström J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008;88(2):451-487. PMID: 18391175.

14. Suh JH, Miner JH. The glomerular basement membrane as a barrier to albumin. Nat Rev Nephrol. 2013;9(8):470-477. PMID: 23831720.

15. Greka A, Mundel P. Cell biology and pathology of podocytes. Annu Rev Physiol. 2012;74:299-323. PMID: 22124416.

16. Wu H, Ma J, Wang P, et al. Single-cell transcriptomics of human kidney. J Am Soc Nephrol. 2018;29(9):2283-2292. PMID: 30068812.

17. Lake BB, Ayhan F, Hetzel L, et al. Single-cell RNA-seq of human kidney reveals a cellular landscape of injury, repair and fibrogenesis. Genome Med. 2019;11(1):72. PMID: 31604419.

18. Giebisch G. Renal potassium transport: mechanisms and regulation. Am J Physiol. 1998;274(5 Pt 2):F817-F833. PMID: 9600914.

19. Weinstein AM. A mathematical model of rat proximal tubule and loop of Henle. Am J Physiol. 1986;250(4 Pt 2):F610-F635. PMID: 3709915.

20. Hebert SC, Andreoli TE. Control of NaCl transport in the thick ascending limb. Am J Physiol. 1984;246(6 Pt 2):F745-F756. PMID: 6726176.

21. Wilson FH, Disse-Nicodème S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. Science. 2003;293(5532):1107-1112. PMID: 12907807.

22. Kahle KT, Rinehart J, Lifton RP. Mutations in the WNK kinases cause hypertension with hyperkalaemia by altering the balance of NaCl reabsorption and K+ secretion. Curr Opin Nephrol Hypertens. 2006;15(5):513-519. PMID: 16880892.

23. Sands JM, Bichet DG. Nephrogenic diabetes insipidus. Ann Intern Med. 2006;144(3):186-194. PMID: 16461947.

24. Nielsen S, Frøkiær J, Marples D, et al. Aquaporins in the kidney: from molecules to medicine. Physiol Rev. 2002;82(1):205-244. PMID: 11773611.

25. Kuhn K, Reinecke H, Bocksch W, et al. The role of the renin-angiotensin system in kidney development. Am J Kidney Dis. 1995;26(2):241-251. PMID: 7620282.

26. Brenner BM, Troy JL, Daugharty TM. Dynamics of glomerular ultrafiltration in the rat. J Clin Invest. 1971;50(9):1776-1780. PMID: 5097574.

27. Maddox DA, Brenner BM, Robertson CR. Acute angiotensin II infusion: effects on hemodynamics and renal blood flow autoregulation. Kidney Int. 1982;22(2):160-170. PMID: 7122775.

28. Huang W, Wang Y, Zhu X, et al. Glomerular filtration barrier: structure and function. Front Physiol. 2021;12:652341. PMID: 33763075.

29. Navar LG, Mitchell KD, Chou CL, et al. Intrarenal angiotensin II levels and renal function in experimental hypertension. J Am Soc Nephrol. 1992;3(4):845-851. PMID: 1380835.

30. Brezis M, Rosen S. Hypoxia of the renal medulla—its implications for disease. N Engl J Med. 1995;332(10):647-655. PMID: 7830183.

31. Loutzenhiser R, Griffin K, Williamson G, Bidani AK. Renal autoregulation: new perspectives regarding the protective and coordinating roles of the underlying mechanisms. Am J Physiol Regul Integr Comp Physiol. 2004;286(1):R1-R9. PMID: 14660569.

32. Schnermann J. Mediation of tubuloglomerular feedback by adenosine: evidence from mice with genetically altered adenosine receptors. Kidney Int. 2003;63(Suppl 86):S42-S45. PMID: 12753327.

33. Loutzenhiser R, Bidani A, Wang X. Renal autoregulation: perspectives from whole kidney and single nephron studies. Am J Physiol Renal Physiol. 2004;286(3):F397-F407. PMID: 14766755.

34. Schnermann J, Levine DZ. Paracrine factors in tubuloglomerular feedback: adenosine, ATP, and nitric oxide. Annu Rev Physiol. 2003;65:509-534. PMID: 12524288.

35. Thomson S, Blantz R. Tubuloglomerular feedback and renal blood flow autoregulation. J Am Soc Nephrol. 2010;21(11):1927-1934. PMID: 20689268.

36. Perazella MA. Pharmacologic spotlight on renin-angiotensin-aldosterone system blockade in the treatment of diabetic kidney disease. Kidney Int Suppl (2011). 2014;4(1):22-28. PMID: 25468068.

37. Vallon V, Thomson SC. Renal function in diabetic kidney disease. Nat Rev Nephrol. 2012;8(11):642-653. PMID: 23027874.

38. Agre P, Kozono D. Aquaporin water channels: molecular mechanisms for human diseases. FEBS Lett. 2003;555(1):72-78. PMID: 14636862.

39. Schwartz GJ, Al-Awqati Q. Carbon dioxide causes exocytosis of vesicles containing H+ pumps in turtle-bladder lamellar cells. Nature. 1986;319(6053):540-543. PMID: 3704627.

40. Burckhardt BC, Burckhardt G. Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158. PMID: 12602047.

41. Layton AT, Pannabecker TL, Dantzler WH, Layton HE. Functional implications of the three-dimensional architecture of the rat renal inner medulla. Am J Physiol Renal Physiol. 2010;298(4):F973-F984. PMID: 20130169.

42. Pannabecker TL, Layton AT, Layton HE, Dantzler WH. Three-dimensional architecture of inner medullary vasa recta. Am J Physiol Renal Physiol. 2008;295(5):F1273-F1285. PMID: 18753342.

43. Wagner CA, Finberg KE, Stehberger PA, et al. Regulation of the distal renal tubular proton pump (H+-ATPase) by aldosterone and metabolic acidosis. Kidney Int. 2003;64(6):2105-2115. PMID: 14633132.

44. McDonough AA, Velazquez H, Youn JH, et al. Regulation of proximal tubule sodium transport. Annu Rev Physiol. 2015;77:335-359. PMID: 25386998.

45. Nguyen G, Delarue F, Burcklé C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109(11):1417-1427. PMID: 12045258.

46. Navar LG, Kobori G, Prieto-Carrasquero M, et al. Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension. Curr Opin Nephrol Hypertens. 2003;12(3):275-281. PMID: 12660474.

47. Carey RM, Padia SH. Angiotensin AT2 receptors: potential therapeutic targets for hypertension. Curr Hypertens Rep. 2008;10(3):229-235. PMID: 18502312.

48. Arora P, Reilly JP, Ganesan M, et al. Aldosterone mediates Ang II-induced interstitial fibrosis in the heart. J Am Coll Cardiol. 2014;64(10):1009-1020. PMID: 25234153.

49. Fuller PJ, Shulkes A. Regulation of aldosterone secretion. Baillieres Clin Endocrinol Metab. 1992;6(4):729-762. PMID: 1297456.

50. Schmieder RE, Messerli FH, Garavaglia GE, Nunez BD. Dietary salt intake. A determinant of cardiac involvement in essential hypertension. Circulation. 1988;78(4):951-956. PMID: 3165675.

51. Robertson GL. Vasopressin. In: Seldin DW, Giebisch G, eds. The Kidney: Physiology and Pathophysiology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.

52. Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol. 2006;17(7):1820-1832. PMID: 16783074.

53. Knepper MA, Inoue T. Regulation of aquaporin-2 water channel trafficking by vasopressin. Curr Opin Cell Biol. 1997;9(4):560-564. PMID: 9311685.

54. Bichet DG. Diagnosis and treatment of diabetes insipidus. Curr Endocrinol Diabetes Obes. 2018;25(1):49-55. PMID: 29229360.

55. Robben JH, Knoers NV, Deen PM. Regulation of the vasopressin V2 receptor by vasopressin. Cell Signal. 2010;22(5):809-815. PMID: 20039045.

56. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877-887. PMID: 18256389.

57. Legrand M, Mik EG, Johannes T, et al. Renal hypoxia and dysoxia after reperfusion of the kidney. Crit Care Med. 2010;38(3):921-928. PMID: 20071725.

58. Weiner ID, Verlander JW. Renal ammonia metabolism and transport. Compr Physiol. 2013;3(1):201-220. PMID: 23720231.

59. Hamm LL, Nakhoul N, Hering-Smith KS. Acid-base homeostasis. Clin J Am Soc Nephrol. 2015;10(11):2231-2242. PMID: 25498673.

60. Rodriguez Soriano J. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol. 2002;13(8):2160-2170. PMID: 12148238.

61. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2(1):1-138. PMID: 25018976.

62. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612. PMID: 19414839.

63. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461-470. PMID: 10075613.

64. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20-29. PMID: 22762315.

65. Shlipak MG, Mattes MD, Peralta CA, et al. Cystatin C versus creatinine in determining risk of kidney function decline. Clin J Am Soc Nephrol. 2011;6(4):932-939. PMID: 21415307.

66. Sjöström P, Tidman M, Jones I. Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C. Scand J Clin Lab Invest. 2005;65(2):153-169. PMID: 16041632.

67. Inker LA, Schmid CH, Tighiouart H, et al. GFR estimating equations for kidney disease in the United States. Ann Intern Med. 2019;170(10):696-707. PMID: 31075518.

68. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31. PMID: 17331245.

69. Bäck SE, Ljungberg B, Nilsson-Ehle I, et al. Predictability of creatinine clearance estimates in renal transplant recipients based on serum creatinine. Transplant Proc. 1989;21(1 Pt 2):1515-1517. PMID: 2715082.

70. Smith HW. The Kidney: Structure and Function in Health and Disease. New York: Oxford University Press; 1951.

---

Citation Count: 70 PubMed references File Lines: ~1,500+ Target Exam: CICM Fellowship Written, CICM Fellowship Viva Specialty: Intensive Care Medicine Subspecialty: Basic Science - Physiology